Skip to main content
Year archive

Purple Biotech Ltd. — 2025 filings

All 100 regulatory filings released by Purple Biotech Ltd. (PPBT) in 2025, sourced directly from the official regulator.

100 Filings
2025 Period
2025 filings (100)
Filing Released Lang
FORM 6-K-Results of the Extraordinary General Meeting of Shareholders of the Company held on December 15, 2025
Declaration of Voting Results & Voting Rights Announcements
2025-12-17 English
FORM 6-K-Results of the Extraordinary General Meeting of Shareholders of the Company held on December 15, 2025
Declaration of Voting Results & Voting Rights Announcements
2025-12-17 English
Immediate Report
Regulatory Filings
2025-12-11 English
Immediate Report
Regulatory Filings
2025-12-11 English
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
Regulatory Filings
2025-12-04 English
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
Regulatory Filings
2025-12-04 English
Other Report or Announcement
Earnings Release Q3 2025
2025-11-16 English
Other Report or Announcement
Regulatory Filings
2025-11-16 English
The company's financial results for the third quarter 2025 were reported abroad
Regulatory Filings
2025-11-16 English
Purple Biotech Achieves Manufacturing Milestone for IM1240, a TriSpecific Antibody from the CAPTN-3 Platform-PR
Regulatory Filings
2025-10-29 English
Purple Biotech Achieves Manufacturing Milestone for IM1240, a TriSpecific Antibody from the CAPTN-3 Platform-PR
Regulatory Filings
2025-10-29 English
6K-Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
Regulatory Filings
2025-10-29 English
6K-Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
Report Publication Announcement FY 2025
2025-10-29 English
Immediate Report of Meeting
Proxy Solicitation & Information Statement
2025-10-29 English
Immediate Report of Meeting
Proxy Solicitation & Information Statement
2025-10-29 English
Immediate Report of Meeting
AGM Information
2025-10-29 English
Immediate Report
Proxy Solicitation & Information Statement
2025-10-29 English
Immediate Report
Report Publication Announcement FY 2025
2025-10-29 English
Other Report or Announcement
Regulatory Filings
2025-10-21 English
Other Report or Announcement
Regulatory Filings FY 2025
2025-10-21 English
AT THE MARKET OFFERING AGREEMENT
Capital/Financing Update
2025-09-21 English
AT THE MARKET OFFERING AGREEMENT
Audit Report / Information Q3 2025
2025-09-21 English
PROSPECTUS SUPPLEMENT (At-the-Market)
Capital/Financing Update
2025-09-21 English
PROSPECTUS SUPPLEMENT (At-the-Market)
Regulatory Filings
2025-09-21 English
CORPORATE PRESETATION- SEPTEMBER 2025
Investor Presentation
2025-09-16 English
CORPORATE PRESETATION- SEPTEMBER 2025
Audit Report / Information FY 2025
2025-09-16 English
Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance
Legal Proceedings Report
2025-09-10 English
Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance
Regulatory Filings
2025-09-10 English
Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
Capital/Financing Update
2025-09-07 English
Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
Report Publication Announcement
2025-09-07 English
Documents regarding the warrants
Capital/Financing Update
2025-09-07 English
Documents regarding the warrants
Regulatory Filings
2025-09-07 English
Prospectus regarding offering of 3,055,000 ADSs and together with warrants
Transaction in Own Shares
2025-09-07 English
Prospectus regarding offering of 3,055,000 ADSs and together with warrants
Regulatory Filings
2025-09-07 English
Announces Pricing of Up To $18 Million Public Offering
Capital/Financing Update
2025-09-04 English
Announces Pricing of Up To $18 Million Public Offering
Capital/Financing Update
2025-09-04 English
Announces New Data Supporting the Unique Design of CAPTN-3
Regulatory Filings
2025-09-04 English
Announces New Data Supporting the Unique Design of CAPTN-3
Regulatory Filings
2025-09-04 English
Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3
Regulatory Filings
2025-09-04 English
Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3
Regulatory Filings
2025-09-04 English
Purple Biotech Expands CAPTN-3 Portfolio-PR
Report Publication Announcement
2025-09-03 English
Purple Biotech Expands CAPTN-3 Portfolio
Regulatory Filings
2025-09-03 English
Purple Biotech Expands CAPTN-3 Portfolio
Regulatory Filings
2025-09-03 English
Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Regulatory Filings
2025-08-27 English
Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Report Publication Announcement
2025-08-27 English
Purple Biotech Reports Second Quarter 2025 Financial Results
Interim / Quarterly Report Q2 2025
2025-08-06 English
Purple Biotech Reports Second Quarter 2025 Financial Results
Report Publication Announcement
2025-08-06 English
6K: Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
Regulatory Filings
2025-07-23 English
6K: Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
Legal Proceedings Report
2025-07-23 English
6K: Purple Biotech Announces Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
Regulatory Filings
2025-06-23 English
6K: Purple Biotech Announces Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
Report Publication Announcement
2025-06-23 English
6K: Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer
Regulatory Filings
2025-06-17 English
6K: Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer
Report Publication Announcement
2025-06-17 English
Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
Regulatory Filings
2025-06-04 English
Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
Report Publication Announcement
2025-06-04 English
Purple Biotech Reports First Quarter 2025 Financial Results
Earnings Release Q1 2025
2025-05-21 English
Purple Biotech Reports First Quarter 2025 Financial Results
Report Publication Announcement
2025-05-21 English
6K: Purple Biotech Appoints Shai Lankry as Chief Financial Officer
Regulatory Filings
2025-05-12 English
6K: Purple Biotech Appoints Shai Lankry as Chief Financial Officer
Board/Management Information
2025-05-12 English
6K: Purple Biotech Corporate Presentation May 2025
Investor Presentation
2025-05-06 English
6K: Purple Biotech Corporate Presentation May 2025
Investor Presentation
2025-05-06 English
6K: Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups
Regulatory Filings
2025-05-03 English
6K: Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups
Report Publication Announcement
2025-05-03 English
6K:Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
Regulatory Filings
2025-04-28 English
6K:Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
Regulatory Filings
2025-04-28 English
6K:Purple Biotech announcing the results of the Annual General Meeting of Shareholders of the Company held on April 22, 2025
AGM Information
2025-04-22 English
6K:Purple Biotech announcing the results of the Annual General Meeting of Shareholders of the Company held on April 22, 2025
AGM Information
2025-04-22 English
Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer
Regulatory Filings
2025-04-16 English
Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer
Report Publication Announcement
2025-04-16 English
Annual General Meeting will be held on the day Tuesday on the date : 22/04/2025 time: 16:30
AGM Information
2025-04-15 English
Annual General Meeting will be held on the day Tuesday on the date : 22/04/2025 time: 16:30
AGM Information
2025-04-15 English
Annual General Meeting will be held on the day Tuesday on the date : 22/04/2025 time: 16:30
AGM Information
2025-04-15 English
6K:the Company’s Annual Meeting of Shareholders held on Tuesday, April 15, 2025, at 4:30 p.m. Israel time was convened and adjourned-will be held on Tuesday, April 22, 2025, at 4:30 p.m. Israel time
AGM Information
2025-04-15 English
6K:the Company’s Annual Meeting of Shareholders held on Tuesday, April 15, 2025, at 4:30 p.m. Israel time was convened and adjourned-will be held on Tuesday, April 22, 2025, at 4:30 p.m. Israel time
AGM Information
2025-04-15 English
o Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025
Regulatory Filings
2025-04-01 English
o Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025
Report Publication Announcement
2025-04-01 English
6K:Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
Regulatory Filings
2025-03-29 English
6K:Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
Regulatory Filings
2025-03-29 English
6K:Purple Biotech Corporate Presentation March 2025
Investor Presentation
2025-03-18 English
6K:Purple Biotech Corporate Presentation March 2025
Report Publication Announcement
2025-03-18 English
Annual report for 2024 on form 20F
Regulatory Filings
2025-03-10 Hebrew (modern)
Annual report for 2024 on form 20F
Report Publication Announcement
2025-03-10 English
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
Earnings Release Q4 2024
2025-03-10 English
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
Report Publication Announcement
2025-03-10 English
The company's financial results for 2024 were reported abroad
Regulatory Filings
2025-03-10 Hebrew (modern)
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy
Regulatory Filings
2025-03-05 English
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy
Regulatory Filings
2025-03-05 English
FORM 6-K- Annual General Meeting will be held on Tuesday, April 15, 2025, at 4:30 p.m. Israel time
AGM Information
2025-03-01 English
FORM 6-K- Annual General Meeting will be held on Tuesday, April 15, 2025, at 4:30 p.m. Israel time
AGM Information
2025-03-01 English
FORM 6-K- Annual General Meeting will be held on Tuesday, April 15, 2025, at 4:30 p.m. Israel time
AGM Information
2025-03-01 English
FORM 6- Annual General Meeting of Shareholders will be held on Tuesday, April 15, 2025, at 4:30 p.m. Israel time
AGM Information
2025-03-01 English
FORM 6- Annual General Meeting of Shareholders will be held on Tuesday, April 15, 2025, at 4:30 p.m. Israel time
AGM Information
2025-03-01 English
6K: Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
Regulatory Filings
2025-02-18 English
6K: Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
Regulatory Filings
2025-02-18 English
Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
Regulatory Filings
2025-02-03 English
Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
Report Publication Announcement
2025-02-03 English
6K- ATM
Regulatory Filings
2025-01-07 English
6K- ATM
Report Publication Announcement
2025-01-07 English
PROSPECTUS SUPPLEMENT (to Prospectus Supplement dated October 17, 2023, to Prospectus dated May 22, 2023)
Capital/Financing Update
2025-01-06 English
PROSPECTUS SUPPLEMENT (to Prospectus Supplement dated October 17, 2023, to Prospectus dated May 22, 2023)
Capital/Financing Update
2025-01-06 English